Congress: Movement Disorder Society (MDS) International Congress 2026
Location: Seoul, Korea — COEX Convention and Exhibition Center
Dates: October 4-8, 2026
This page synthesizes the latest research on Parkinson's disease genetics and molecular mechanisms presented at MDS 2026, with emphasis on key genetic risk factors, molecular pathways, and therapeutic implications.
MDS 2026 showcased significant advances in understanding the genetic architecture of Parkinson's disease and the molecular mechanisms underlying neurodegeneration. Key themes included:
LRRK2 (Leucine-Rich Repeat Kinase 2) is the most common monogenic cause of Parkinson's disease[1]. Pathogenic variants include:
| Variant | Domain | Effect | Population Prevalence |
|---|---|---|---|
| G2019S | Kinase | ↑ Kinase activity 2-3x | ~5% familial, ~1% sporadic PD |
| R1441C/G/H | ROC | ↓ GTPase activity | Basque, worldwide |
| I2020T | Kinase | ↑ Kinase activity | Japanese families |
LRRK2 participates in multiple cellular pathways relevant to PD pathogenesis:
Multiple LRRK2 inhibitors have advanced through clinical development:
| Drug | Company | Mechanism | Stage |
|---|---|---|---|
| DNL151/DNL312 | Denali/Biogen | ATP-competitive | Phase 2/3 |
| BIIB122 | Biogen | ATP-competitive | Phase 2b |
| PF-06649751 | Pfizer | ATP-competitive | Phase 1 |
Key challenges addressed at MDS 2026:
Novel therapeutic modalities include:
See LRRK2 Pathway in PD for detailed mechanism coverage.
Glucocerebrosidase (GBA1) variants are the most significant genetic risk factor for sporadic PD, with 5-10% of PD patients carrying pathogenic variants[3].
GBA-PD represents a distinct clinical subtype:
| Pathway | Dysfunction | Therapeutic Target |
|---|---|---|
| Lysosomal function | ↓ GCase activity | Enzyme enhancement |
| Alpha-synuclein clearance | ↑ Aggregation | Ambroxol, substrate reduction |
| Lipid metabolism | ↑ Glucosylceramide | Substrate reduction therapy |
| Autophagy | Impaired clearance | Autophagy inducers |
See GBA Pathway in PD for detailed coverage.
SNCA encodes alpha-synuclein, the key protein in Lewy body pathology:
| Variant | Effect | Phenotype |
|---|---|---|
| A53T (SNCAm) | Early onset | Rapid progression, autonomic dysfunction |
| A30P | Incomplete penetrance | Variable |
| Triplication | Gene dose effect | Early onset, severe dementia |
| Duplication | Gene dose effect | Typical PD presentation |
MDS 2026 featured updates on clinical validation of alpha-synuclein SAAs:
| Assay | Sensitivity | Specificity | Sample |
|---|---|---|---|
| RT-QuIC (CSF) | 87-95% | 90-95% | CSF |
| PMCA (CSF) | 88-96% | 92-98% | CSF |
| SynuLight (blood) | 80-85% | 85-90% | Blood |
Key applications:
See Alpha-Synuclein Aggregation Pathway for detailed mechanisms.
| Gene | PARK Number | Protein Function | Phenotype |
|---|---|---|---|
| PRKN (PARK2) | PARK2 | E3 ubiquitin ligase | Early onset, dystonia |
| PINK1 (PARK6) | PARK6 | Mitochondrial kinase | Early onset |
| DJ-1 (PARK7) | PARK7 | Oxidative stress response | Early onset |
| ATP13A2 (PARK9) | PARK9 | Lysosomal ATPase | Juvenile parkinsonism, dementia |
| Gene | PARK Number | Protein Function | Phenotype |
|---|---|---|---|
| SNCA (PARK1/4) | PARK1/4 | Synaptic protein | Early onset, dementia |
| LRRK2 (PARK8) | PARK8 | Kinase/GTPase | Typical PD |
| VPS35 (PARK17) | PARK17 | Retromer component | Late onset, good levodopa response |
Recent discoveries include:
Large-scale GWAS have identified >90 PD risk loci. Key findings from recent multi-ethnic studies:
| Population | Novel Loci | Notable Genes |
|---|---|---|
| European | 78 loci | LRRK2, GBA, SNCA |
| East Asian | 15 loci | FAM47E, SCARB2 |
| African | Novel variants | Population-specific |
| Latino | 8 loci | GCH1, MIR4697 |
Clinical implementation of PRS is advancing:
MDS 2026 highlighted gene-environment interplay:
| Genetic Subtype | Therapeutic Strategy | Development Stage |
|---|---|---|
| LRRK2 G2019S | Kinase inhibitors | Phase 2/3 |
| GBA1 | Enzyme enhancement | Phase 2 |
| SNCA | Immunotherapy | Phase 2/3 |
| PRKN/PINK1 | Mitophagy activators | Preclinical |
| ATP13A2 | Lysosomal function | Preclinical |
Tier 1 (all PD patients):
Tier 2 (early onset, family history):
Key considerations:
This page synthesizes content relevant to MDS 2026 presentations on PD genetics and molecular mechanisms. For the latest updates, check the MDS Congress website.
Cookson MR. "The role of LRRK2 in Parkinson's disease". Nat Rev Neurosci. 2023. ↩︎
Tolosa E, Vila M. "LRRK2 in Parkinson disease: Challenges of clinical trials". Nat Rev Neurol. 2022. ↩︎
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease. Transl Neurodegener. 2024. ↩︎